The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Neoadjuvant capecitabine and oxaliplatin (CAPOX) followed by chemoradiation (CRT) in high-risk rectal cancer: A single-institution experience.
Saif Ahmad
No relevant relationships to disclose
Deepak Parashar
No relevant relationships to disclose
Catherine Rachel Jephcott
No relevant relationships to disclose
Hugo Ford
Consultant or Advisory Role - Roche
Honoraria - Roche/Genentech
Other Remuneration - Roche/Genentech
Charles Wilson
Disclosure not yet available